Genencor International Inc. is making good on its plans to obtain access to antigen discovery technologies and delivery constructs for its vaccine programs, announcing that it will partner with Epimmune Inc. to develop therapeutic DNA vaccines. But GCOR won't stop at DNA vaccines, planning to make other platform acquisitions so that it can choose the best among several approaches for any given indication.

GCOR already had identified antigen discovery as a key partnering area (see BioCentury, Feb. 12). Under last week's deal, GCOR received an exclusive license to EPMN's epitope identification system (EIS